The Council to Advance Human Health (CAHH) was developed as a catalyst for a focused model of translation, providing small targeted grants for investigators to develop promising projects towards an exit. Eligible investigators are invited to present their projects to obtain funding up to $75,000.
Some spin-outs from CAHH include:
Convelo Therapeutics, Inc.
Haima Therapeutics
Read about Haima in the press:
Luminary Therapeutics, Inc.
Read about Luminary in The Daily:
Mosaic Immunoengineering, Inc.
Read about Mosaic in the press:
- Mosaic ImmunoEngineering Inc. signs license-option to advance novel immunotherapy to treat cancer and infectious diseases
- A Common Plant Virus Is an Unlikely Ally in the War on Cancer
- Mosaic ImmunoEngineering Inc. signs license-option to advance novel immunotherapy to treat cancer and infectious diseases
Rodeo Therapeutics, Inc.
Q2 Pharma
Read about Q2 in The Daily:
- Case Western Reserve embarks on innovative path to treat infections of drug-resistant superbugs such as MRSA without antibiotics
- Case Western Reserve researchers cure drug-resistant infections without antibiotics
- $1M, two-year grant from Dr. Ralph and Marian Falk Medical Research Trust to advance CWRU research on therapies for Huntington’s disease
Tevard Biosciences
Read about Tevard in The Daily: